Scarica l'app Stockscreener
0.99
2.94%
-0.03
Dopo l'orario di chiusura:
.99
Revelation Biosciences Inc Borsa (REVB) Ultime notizie
Revelation Biosciences, Inc. Warrant 2022-10.01.27 on Revelatn Biosci Financial Disclosures & SEC Filings - TradingView
Price to sales forward of Revelation Biosciences, Inc. – NASDAQ:REVB - TradingView
Price to earnings forward of Revelation Biosciences, Inc. – NASDAQ:REVBW - TradingView
REVB Q1 2026 Earnings: EPS Misses Estimates by Wide Margin, Stock Gains 6%Analyst Consensus Shift - dars.gov.et
Price to earnings forward of Revelation Biosciences, Inc. – BOATS:REVBW - TradingView
Revelation Biosciences, Inc. Actuals & Estimates (NASDAQ:REVB) - TradingView
Revelation Biosciences, Inc. Actuals & Estimates (BOATS:REVB) - TradingView
REVB Forecast — Price Target — Prediction for 2027 - TradingView
Revelation Biosciences Inc (REVBW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Revelation Biosciences Amends Executive Agreements and Bylaws, Announces CEO and CFO Changes – June 2026 - Minichart
Revelation Biosciences Updates Executive Contracts, Shareholder Actions - TipRanks
Revelation Biosciences updates employment agreements for CEO James Rolke and CFO Chester S. Zygmont, III - TradingView
Revelation Biosciences (NASDAQ: REVB) expands CEO/CFO protections and secures reverse split authority - Stock Titan
Revelation Biosciences Inc (REVB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Revelation Biosciences Inc (REVBW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Revelation Biosciences Inc (REVBW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Revelation Biosciences Inc (REVBW) Institutional Confidence - TradingKey
Revelation Biosciences Inc (REVBW) Valuation: PE, PB & Fair Value Analysis - TradingKey
Revelation Biosciences Inc (REVBW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Revelation Biosciences Inc (REVB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Revelation Biosciences Inc (REVB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Revelation Biosciences Inc (REVB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Revelation Biosciences Inc (REVB) Valuation: PE, PB & Fair Value Analysis - TradingKey
Revelation Biosciences Inc (REVBW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Revelation Biosciences Inc (REVBW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Revelation Biosciences Inc - TradingKey
Revelation Biosciences Inc (REVB) Institutional Confidence - TradingKey
Revelation Biosciences Inc (REVB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Revelation Biosciences Inc (REVB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Revelation Biosciences Inc (REVB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Revelation Biosciences, Inc. Financial Disclosures & SEC Filings - TradingView
REVB SEC FilingsRevelation Biosciences 10-K, 10-Q, 8-K Forms - Stock Titan
REVB Q1 2026 Earnings: EPS Misses Estimates by Wide Margin; No Revenue ReportedEPS Revision Trend - newsline.com
REVB Q1 2026 Earnings: Wider-than-Expected Loss Amid Pre-Revenue StageCFO Commentary Report - newsline.com
Revelation Biosciences forms advisory board for AKI trial - Investing.com
Revelation Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Newark Advocate
Revelation Biosciences expands AKI advisory board - Investing.com UK
Revel Releases Updated Corporate Presentation and Posts It to Website - TradingView
Revelation Biosciences (NASDAQ: REVB) furnishes new corporate presentation - Stock Titan
Revelation Biosciences expands AKI advisory board By Investing.com - Investing.com South Africa
Revelation Biosciences Expands Acute Kidney Injury Advisory Board - Rutland Herald
REVB Q1 2026 Earnings: Wider-Than-Expected Loss Highlights Pre-Revenue StageSubscription Growth Report - newsline.com
Revelation Biosciences (REVB) Shows Minimal Movement as Shares Trade Near Key SupportTime Weighted Price - newsline.com
REVB Q1 2026 Earnings: Significant EPS Miss as Cash Burn Continues Without RevenueReturn On Assets - thelegaladvocate.com
Revelation Biosciences (REVB) Inches Higher, Holding Above Key Support at $1.02Bear Pennant - The Legal Advocate
REVB Q1 2026 Earnings: Significant EPS Miss Amid Early-Stage DevelopmentEarnings Revision Downgrade - The Legal Advocate
REVB Q1 2026 Earnings: Staggering EPS Miss Highlights Ongoing Clinical Development CostsBook Value Growth - The Legal Advocate
Revelation Biosciences Inc. (REVB) Edges Lower, Maintains Support Near $1.01Exhaustion Gap - The Legal Advocate
REVB Q1 2026 Earnings: Wider-than-Expected Loss Highlights Pre-Revenue ChallengesEarnings Outlook Update - newsline.com
REVBRevelation Biosciences Inc Stock Price and Quote - Finviz
Revelation Biosciences (REVB) Faces Slight Decline as Key Support Levels Are TestedWave Extension - The Legal Advocate
Revelation Biosciences Q1 2026 Earnings: EPS Miss Highlights Ongoing Pre-Revenue StageStock Analysis Community - Newser
1.17%
2.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):